Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Comparative Effectiveness of Anti–Growth Factor Therapies for Diabetic Macular Edema

Comparative Effectiveness of Anti–Growth Factor Therapies for Diabetic Macular Edema EVIDENCE TO PRACTICE Comparative Effectiveness of Anti–Growth Factor Therapies for Diabetic Macular Edema Summary of Primary Findings and Conclusions IABETIC MACULAR sual acuity (BCVA); ocular and LIMITATIONS OF edema (DME) is a systemic adverse events were also THE EVIDENCE common conse- evaluated. None of the available trials quence of diabetic involved head-to-head comparisons As noted herein, there were no pub- D retinopathy and a of any of the 4 agents. Only 1 trial of lished randomized trials directly leading cause of significantly im- aflibercept and 2 trials of pegaptanib comparing any of the anti-VEGF paired vision among patients with have been published to date. agents of interest. The trials dif- diabetes. For many years, the stan- Findings across all agents were fered substantially in terms of pa- dard of care has been to treat DME highly consistent. Improvement in tient eligibility criteria, treatment with laser photocoagulation treat- visual acuity relative to control (ie, protocol (eg, laser photocoagula- ments to the macula. Recently, evi- laser photocoagulation and/or sham tion control vs use of laser as a “res- dence has begun to accumulate cue” modality only), and duration injection) was seen with all agents. demonstrating the effectiveness of of follow-up. Trials http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Comparative Effectiveness of Anti–Growth Factor Therapies for Diabetic Macular Edema

JAMA Internal Medicine , Volume 172 (13) – Jul 9, 2012

Loading next page...
 
/lp/american-medical-association/comparative-effectiveness-of-anti-growth-factor-therapies-for-diabetic-ViFsndjhmo
Publisher
American Medical Association
Copyright
Copyright 2012 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinternmed.2012.2335
pmid
22688778
Publisher site
See Article on Publisher Site

Abstract

EVIDENCE TO PRACTICE Comparative Effectiveness of Anti–Growth Factor Therapies for Diabetic Macular Edema Summary of Primary Findings and Conclusions IABETIC MACULAR sual acuity (BCVA); ocular and LIMITATIONS OF edema (DME) is a systemic adverse events were also THE EVIDENCE common conse- evaluated. None of the available trials quence of diabetic involved head-to-head comparisons As noted herein, there were no pub- D retinopathy and a of any of the 4 agents. Only 1 trial of lished randomized trials directly leading cause of significantly im- aflibercept and 2 trials of pegaptanib comparing any of the anti-VEGF paired vision among patients with have been published to date. agents of interest. The trials dif- diabetes. For many years, the stan- Findings across all agents were fered substantially in terms of pa- dard of care has been to treat DME highly consistent. Improvement in tient eligibility criteria, treatment with laser photocoagulation treat- visual acuity relative to control (ie, protocol (eg, laser photocoagula- ments to the macula. Recently, evi- laser photocoagulation and/or sham tion control vs use of laser as a “res- dence has begun to accumulate cue” modality only), and duration injection) was seen with all agents. demonstrating the effectiveness of of follow-up. Trials

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Jul 9, 2012

References